FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379600563> ?p ?o ?g. }

• W4379600563 endingPage "1478" @default.
• W4379600563 startingPage "1469" @default.
• W4379600563 abstract "Evogliptin (EV) is a novel dipeptidyl peptidase-4 inhibitor (DPP4i) for glycemic control in patients with type 2 diabetes mellitus (T2DM). This study evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between EV and sodium glucose cotransporter-2 inhibitors (SGLT2i) in healthy volunteers since combination therapy of DPP4i and SGLT2i has been considered as an effective option for T2DM treatment. A randomized, open-label, multiple-dose, two-arm, three-period, three treatments, two-sequence crossover study was conducted in healthy Korean volunteers. In arm 1, subjects were administered 5 mg of EV once daily for 7 days, 25 mg of empagliflozin (EP) once daily for 5 days, and the combination once daily for 5 days (EV + EP). In arm 2, subjects were administered 5 mg of EV once daily for 7 days, 10 mg of dapagliflozin (DP) once daily for 5 days, and the combination once daily for 5 days (EV + DP). Serial blood samples were collected for PK analysis, and oral glucose tolerance tests were conducted for PD analysis. In each arm, a total of 18 subjects completed the study. All adverse events (AEs) were mild with no serious AEs. The geometric mean ratio and confidence interval of the main PK parameters (maximum concentration of the drug in plasma at steady state and area under the plasma drug concentration-time curve within a dosing interval at a steady state) between EV and either EP or DP alone were not significantly altered by co-administration. Administration of EV + EP or EV + DP did not result in significant PD changes, as determined by the glucose-lowering effect. Administration of EV + EP or EV + DP had no significant effects on the PK profiles of each drug. All treatments were well-tolerated." @default.
• W4379600563 created "2023-06-08" @default.
• W4379600563 creator A5048028604 @default.
• W4379600563 creator A5052341705 @default.
• W4379600563 creator A5068295425 @default.
• W4379600563 creator A5073740836 @default.
• W4379600563 creator A5075482380 @default.
• W4379600563 creator A5076740216 @default.
• W4379600563 creator A5085332322 @default.
• W4379600563 date "2023-06-21" @default.
• W4379600563 modified "2023-10-16" @default.
• W4379600563 title "Pharmacokinetic and pharmacodynamic <scp>drug–drug</scp> interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers" @default.
• W4379600563 cites W1969367759 @default.
• W4379600563 cites W1977038312 @default.
• W4379600563 cites W2038961968 @default.
• W4379600563 cites W2048352852 @default.
• W4379600563 cites W2054185381 @default.
• W4379600563 cites W2074588733 @default.
• W4379600563 cites W2075537424 @default.
• W4379600563 cites W2078992128 @default.
• W4379600563 cites W2101865653 @default.
• W4379600563 cites W2105660444 @default.
• W4379600563 cites W2123629330 @default.
• W4379600563 cites W2134652590 @default.
• W4379600563 cites W2147187810 @default.
• W4379600563 cites W2150855258 @default.
• W4379600563 cites W2161311866 @default.
• W4379600563 cites W2161852973 @default.
• W4379600563 cites W2510708214 @default.
• W4379600563 cites W2569951022 @default.
• W4379600563 cites W2586323361 @default.
• W4379600563 cites W2746329033 @default.
• W4379600563 cites W2790576751 @default.
• W4379600563 cites W2972325112 @default.
• W4379600563 cites W3081655479 @default.
• W4379600563 cites W3093971607 @default.
• W4379600563 cites W4379600563 @default.
• W4379600563 doi "https://doi.org/10.1111/cts.13566" @default.
• W4379600563 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37282359" @default.
• W4379600563 hasPublicationYear "2023" @default.
• W4379600563 type Work @default.
• W4379600563 citedByCount "1" @default.
• W4379600563 countsByYear W43796005632023 @default.
• W4379600563 crossrefType "journal-article" @default.
• W4379600563 hasAuthorship W4379600563A5048028604 @default.
• W4379600563 hasAuthorship W4379600563A5052341705 @default.
• W4379600563 hasAuthorship W4379600563A5068295425 @default.
• W4379600563 hasAuthorship W4379600563A5073740836 @default.
• W4379600563 hasAuthorship W4379600563A5075482380 @default.
• W4379600563 hasAuthorship W4379600563A5076740216 @default.
• W4379600563 hasAuthorship W4379600563A5085332322 @default.
• W4379600563 hasBestOaLocation W43796005631 @default.
• W4379600563 hasConcept C111113717 @default.
• W4379600563 hasConcept C112705442 @default.
• W4379600563 hasConcept C126322002 @default.
• W4379600563 hasConcept C134018914 @default.
• W4379600563 hasConcept C142724271 @default.
• W4379600563 hasConcept C204787440 @default.
• W4379600563 hasConcept C27081682 @default.
• W4379600563 hasConcept C2775887513 @default.
• W4379600563 hasConcept C2777180221 @default.
• W4379600563 hasConcept C2777422806 @default.
• W4379600563 hasConcept C2779306644 @default.
• W4379600563 hasConcept C2780473172 @default.
• W4379600563 hasConcept C555293320 @default.
• W4379600563 hasConcept C71924100 @default.
• W4379600563 hasConcept C87813604 @default.
• W4379600563 hasConcept C98274493 @default.
• W4379600563 hasConceptScore W4379600563C111113717 @default.
• W4379600563 hasConceptScore W4379600563C112705442 @default.
• W4379600563 hasConceptScore W4379600563C126322002 @default.
• W4379600563 hasConceptScore W4379600563C134018914 @default.
• W4379600563 hasConceptScore W4379600563C142724271 @default.
• W4379600563 hasConceptScore W4379600563C204787440 @default.
• W4379600563 hasConceptScore W4379600563C27081682 @default.
• W4379600563 hasConceptScore W4379600563C2775887513 @default.
• W4379600563 hasConceptScore W4379600563C2777180221 @default.
• W4379600563 hasConceptScore W4379600563C2777422806 @default.
• W4379600563 hasConceptScore W4379600563C2779306644 @default.
• W4379600563 hasConceptScore W4379600563C2780473172 @default.
• W4379600563 hasConceptScore W4379600563C555293320 @default.
• W4379600563 hasConceptScore W4379600563C71924100 @default.
• W4379600563 hasConceptScore W4379600563C87813604 @default.
• W4379600563 hasConceptScore W4379600563C98274493 @default.
• W4379600563 hasIssue "8" @default.
• W4379600563 hasLocation W43796005631 @default.
• W4379600563 hasLocation W43796005632 @default.
• W4379600563 hasLocation W43796005633 @default.
• W4379600563 hasOpenAccess W4379600563 @default.
• W4379600563 hasPrimaryLocation W43796005631 @default.
• W4379600563 hasRelatedWork W1971830765 @default.
• W4379600563 hasRelatedWork W2199901734 @default.
• W4379600563 hasRelatedWork W2531277573 @default.
• W4379600563 hasRelatedWork W2807204184 @default.
• W4379600563 hasRelatedWork W3098093747 @default.
• W4379600563 hasRelatedWork W3143290529 @default.
• W4379600563 hasRelatedWork W3179513936 @default.
• W4379600563 hasRelatedWork W4233501496 @default.

• next